A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
Recruiting now · Phase 2
Conditions studied: Multiple Myeloma
In brief
The purpose of this study is to evaluate how well JNJ-79635322 works (efficacy) in participants with Relapsed or Refractory Multiple Myeloma (RRMM; a cancer that forms in a type of white blood cells called a plasma cell. Cancer is called relapsed if it comes back after treatment and is called 'refractory' if does not respond to treatment) who have received at least 3 prior lines of therapy.
Key facts
- Study ID
- NCT07266441
- Run by
- Janssen Research & Development, LLC
- People needed
- 157
- Starts
- 2026-02-08
- Expected to finish
- 2028-12-12
- Last updated by the study team
- 2026-07-31
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Banner MD Anderson Cancer Center — Gilbert, Arizona, United States (enrolling)
- City of Hope — Duarte, California, United States (enrolling)
- City of Hope Orange County Lennar Foundation Cancer Center — Irvine, California, United States (enrolling)
- Cancer and Blood Specialty Clinic — Los Alamitos, California, United States (enrolling)
- University of California San Francisco — San Francisco, California, United States (enrolling)
- Rocky Mountain Cancer Centers — Aurora, Colorado, United States (enrolling)
- Colorado Blood Cancer Institute — Denver, Colorado, United States (enrolling)
- Cancer Specialists of North Florida — Jacksonville, Florida, United States (enrolling)
- Emory University — Atlanta, Georgia, United States (enrolling)
- Northside Hospital Cancer Institute — Atlanta, Georgia, United States (enrolling)
- Cancer Care Specialists of Central Illinois — O'Fallon, Illinois, United States (enrolling)
- University of Iowa — Iowa City, Iowa, United States (enrolling)
- Mission Cancer Blood — Waukee, Iowa, United States (enrolling)
- Massachusetts General Hospital — Boston, Massachusetts, United States (enrolling)
- Rutgers Cancer Institute — New Brunswick, New Jersey, United States (enrolling)
- Memorial Sloan Kettering Cancer Center — New York, New York, United States (enrolling)
- Levine Cancer Institute — Charlotte, North Carolina, United States (enrolling)
- Cleveland Clinic Foundtation — Cleveland, Ohio, United States (enrolling)
- Oncology Associates of Oregon PC Willamette Valley Cancer Institute — Eugene, Oregon, United States (enrolling)
- University of Pennsylvania — Philadelphia, Pennsylvania, United States (enrolling)
- SCRI Oncology Partners — Nashville, Tennessee, United States (enrolling)
- Tennessee Oncology, PLLC — Nashville, Tennessee, United States (enrolling)
- Texas Oncology — Austin, Texas, United States (enrolling)
- MD Anderson Cancer Center — Houston, Texas, United States (enrolling)
- O Neal Comprehensive Cancer Center at UAB — Birmingham, Alabama, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.